TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
Investing.com - Neuroone Medical (NASDAQ: NMTC) reported second quarter EPS of $-0.070, $0.02 better than the analyst estimate of $-0.090. Revenue for the quarter came in at $1.4M versus the consensus estimate of $2.4M.
Guidance
Neuroone Medical sees FY 2025 revenue of $8.000M-$10.000M versus the analyst consensus of $8.160M.
Neuroone Medical’s stock price closed at $0.62. It is down -45.350% in the last 3 months and down -45.350% in the last 12 months.
Neuroone Medical saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Neuroone Medical’s stock price’s past reactions to earnings here.
According to InvestingPro, Neuroone Medical’s Financial Health score is "fair performance".
Check out Neuroone Medical’s recent earnings performance, and Neuroone Medical’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar